Skip to content
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
Read more about the article Interviewing Graeme Mcfarlane – Accelerating access to psychedelic therapy.

Interviewing Graeme Mcfarlane – Accelerating access to psychedelic therapy.

  • Post author:barneyneal96
  • Post published:December 15, 2020
  • Post category:Interviews

Interviewing Graeme Mcfarlane Chief Commercial Officer. Graeme shares a deep insight into Albert Labs, his expertise and why he can help Albert Labs succeed. He shares further insights into Real…

Continue ReadingInterviewing Graeme Mcfarlane – Accelerating access to psychedelic therapy.

Recent Posts

  • Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors
  • Albert Labs Management and Board of Director Announcement
  • Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement

Recent Comments

  • Randal Elliott on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Nicholas Stewart on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Camille Ortega on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Kelly Lambert on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Dean Phillips on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2024 Albert Labs. All Rights Reserved

  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact [email protected]

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

  • This field is for validation purposes and should be left unchanged.
Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.